Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | ILK | Q13418 | 5/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 4/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15721008 | 0.85 | ILK (0.47) | APPKDM4ERECQLILKEGFR | |
| SCHEMBL15071344 | 0.84 | KDM4E (0.41) | APPKDM4ERECQLALDH1A1MAPT | |
| SCHEMBL16106194 | 0.82 | TSHR (0.40) | APPKDM4ERECQLALDH1A1MAPT | |
| SCHEMBL15516657 | 0.82 | TSHR (0.40) | APPKDM4ERECQLALDH1A1MAPT | |
| SCHEMBL16931587 | 0.82 | TSHR (0.40) | APPKDM4ERECQLALDH1A1MAPT | |
| SCHEMBL15721091 | 0.82 | TSHR (0.40) | APPKDM4ERECQLALDH1A1MAPT | |
| SCHEMBL15517115 | 0.82 | TSHR (0.40) | APPKDM4ERECQLALDH1A1MAPT | |
| SCHEMBL17640942 | 0.78 | KCNH2 (0.42) | ALDH1A1MAPTAR | |
| SCHEMBL19224011 | 0.77 | ALDH1A1 (0.44) | RECQLSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL15720106 | 0.76 | ALDH1A1 (0.37) | APPKDM4ERECQLALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9732063-B2 | Kinase inhibitors | RESPIVERT LIMITED (GB) | 2017-08-15 | — | — | US | disclosed |
| EP-2925742-B1 | KINASE INHIBITORS | RESPIVERT LTD (GB) | 2016-10-26 | — | — | EP | disclosed |
| US-20150329523-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2015-11-19 | — | — | US | disclosed |
| EP-2925742-A1 | KINASE INHIBITORS | Respivert Limited (GB) | 2015-10-07 | — | — | EP | disclosed |
| WO-2014076484-A1 | KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2014-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329523-A1 | KINASE INHIBITORS | SYK, SRC, BTK | APP 3400/4885KDM4E 2536/4885RECQL 1303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.